BR112012008370B8 - anticorpos monoclonais - Google Patents
anticorpos monoclonaisInfo
- Publication number
- BR112012008370B8 BR112012008370B8 BR112012008370A BR112012008370A BR112012008370B8 BR 112012008370 B8 BR112012008370 B8 BR 112012008370B8 BR 112012008370 A BR112012008370 A BR 112012008370A BR 112012008370 A BR112012008370 A BR 112012008370A BR 112012008370 B8 BR112012008370 B8 BR 112012008370B8
- Authority
- BR
- Brazil
- Prior art keywords
- fibrinogen
- fibrin
- domain
- monoclonal antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24801409P | 2009-10-02 | 2009-10-02 | |
| US61/248,014 | 2009-10-02 | ||
| PCT/US2010/050873 WO2011041518A1 (en) | 2009-10-02 | 2010-09-30 | Monoclonal antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012008370A2 BR112012008370A2 (pt) | 2016-11-29 |
| BR112012008370B1 BR112012008370B1 (pt) | 2020-12-22 |
| BR112012008370B8 true BR112012008370B8 (pt) | 2021-05-25 |
Family
ID=43826649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012008370A BR112012008370B8 (pt) | 2009-10-02 | 2010-09-30 | anticorpos monoclonais |
Country Status (38)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
| WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| WO2012162698A1 (en) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of immune disorders |
| WO2013185055A1 (en) | 2012-06-07 | 2013-12-12 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of pin1 |
| EP2968548B1 (en) * | 2013-03-15 | 2020-09-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| EP3091996B1 (en) * | 2014-01-11 | 2024-04-10 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Compositions and methods for in vitro assays of fibrin activity |
| WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
| WO2016011265A2 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for pin1-associated disorders |
| US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| SG11201910113PA (en) * | 2017-05-02 | 2019-11-28 | Nat Cancer Center Japan | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate |
| CA3178880A1 (en) | 2020-03-31 | 2021-10-07 | National Cancer Center | Fibrin-binding antibody and pharmaceutical composition containing antibody |
| WO2022133028A1 (en) * | 2020-12-16 | 2022-06-23 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Use of fibrin-targeting immunotherapy to reduce coronavirus pathogenesis |
| WO2022159776A1 (en) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
| US20240279321A1 (en) * | 2021-06-18 | 2024-08-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE |
| WO2022266539A2 (en) * | 2021-06-18 | 2022-12-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE |
| WO2024044583A1 (en) * | 2022-08-22 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Human anti-fibrin antibodies and uses thereof |
| EP4676499A2 (en) * | 2023-03-10 | 2026-01-14 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Methods and compositions for cellular immunotherapy- fib4 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031675A1 (en) * | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| EP2314620B1 (en) * | 2004-05-27 | 2013-06-05 | Crucell Holland B.V. | Method of identifying binding molecules capable of neutralizing rabies virus |
| WO2007038407A2 (en) * | 2005-09-23 | 2007-04-05 | The Regents Of The University Of California | Compositions and methods for treating nervous system disorders |
-
2010
- 2010-09-30 HU HUE10821238A patent/HUE031571T2/en unknown
- 2010-09-30 MY MYPI2012001408A patent/MY159359A/en unknown
- 2010-09-30 AU AU2010300559A patent/AU2010300559B2/en active Active
- 2010-09-30 NZ NZ598770A patent/NZ598770A/en unknown
- 2010-09-30 CA CA2774256A patent/CA2774256C/en active Active
- 2010-09-30 HR HRP20170110TT patent/HRP20170110T1/hr unknown
- 2010-09-30 DK DK10821238.2T patent/DK2483416T3/en active
- 2010-09-30 ES ES10821238.2T patent/ES2614939T3/es active Active
- 2010-09-30 EA EA201270416A patent/EA023477B1/ru unknown
- 2010-09-30 SM SM20170083T patent/SMT201700083T1/it unknown
- 2010-09-30 LT LTEP10821238.2T patent/LT2483416T/lt unknown
- 2010-09-30 SI SI201031390A patent/SI2483416T1/sl unknown
- 2010-09-30 PT PT108212382T patent/PT2483416T/pt unknown
- 2010-09-30 KR KR1020127011293A patent/KR101793221B1/ko not_active Expired - Fee Related
- 2010-09-30 MX MX2012003811A patent/MX2012003811A/es active IP Right Grant
- 2010-09-30 GE GEAP201012676A patent/GEP20156214B/en unknown
- 2010-09-30 EP EP10821238.2A patent/EP2483416B1/en active Active
- 2010-09-30 CN CN201080046037.8A patent/CN102575277B/zh active Active
- 2010-09-30 JP JP2012532307A patent/JP5883389B2/ja active Active
- 2010-09-30 PL PL10821238T patent/PL2483416T3/pl unknown
- 2010-09-30 BR BR112012008370A patent/BR112012008370B8/pt active IP Right Grant
- 2010-09-30 WO PCT/US2010/050873 patent/WO2011041518A1/en not_active Ceased
- 2010-09-30 PH PH1/2012/500551A patent/PH12012500551A1/en unknown
- 2010-09-30 GE GEAP201013232A patent/GEP20166458B/en unknown
- 2010-09-30 UA UAA201203044A patent/UA108860C2/ru unknown
- 2010-10-01 AR ARP100103578A patent/AR078490A1/es not_active Application Discontinuation
- 2010-10-01 TW TW099133559A patent/TWI511741B/zh active
-
2012
- 2012-03-14 IL IL218621A patent/IL218621B/en not_active IP Right Cessation
- 2012-03-16 CR CR20120127A patent/CR20120127A/es unknown
- 2012-03-20 US US13/425,020 patent/US8877195B2/en active Active
- 2012-03-27 ZA ZA2012/02227A patent/ZA201202227B/en unknown
- 2012-03-29 DO DO2012000089A patent/DOP2012000089A/es unknown
- 2012-03-30 CL CL2012000788A patent/CL2012000788A1/es unknown
- 2012-03-30 GT GT201200096A patent/GT201200096A/es unknown
- 2012-03-30 TN TNP2012000149A patent/TN2012000149A1/en unknown
- 2012-04-12 IN IN3154DEN2012 patent/IN2012DN03154A/en unknown
- 2012-04-18 CO CO12064155A patent/CO6440561A2/es active IP Right Grant
- 2012-04-30 MA MA34824A patent/MA33704B1/fr unknown
-
2017
- 2017-01-30 CY CY20171100132T patent/CY1118540T1/el unknown
- 2017-02-08 SM SM201700083T patent/SMT201700083B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012008370B8 (pt) | anticorpos monoclonais | |
| Bertolaccini et al. | Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant | |
| BRPI0518994A2 (pt) | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas | |
| BR112013010213A2 (pt) | anticorpos que unem ligantes solúveis de receptores de célula t | |
| BR112020002012A8 (pt) | Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 | |
| NZ593964A (en) | Human anti-alpha-synuclein autoantibodies | |
| BR112018016337A2 (pt) | anticorpos monoclonais da proteína ns1 de vírus antidengue | |
| WO2010009987A3 (en) | Diagnostic antibody assay | |
| BR112013023540A2 (pt) | anticorpo, kit e método para a determinação de peptídeos amilóides | |
| BRPI0922350B8 (pt) | anticorpo humano que se liga ao fator de tecido humano e molécula biespecífica e seus usos, célula hospedeira eucariótica ou procariótica recombinante, composição farmacêutica, método para a produção de um anticorpo, composição de diagnóstico, método para detectar a presença de fator de tecido em uma amostra in vitro, kit para detectar a presença de fator de tecido em uma amostra eanticorpo antiidiotípico | |
| BRPI0923199B8 (pt) | método para determinar a presença de anticorpos de fixação de complemento | |
| CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
| EP3523639A4 (en) | DETECTION REAGENTS AND ELECTRODE ARRANGEMENTS FOR DIAGNOSTIC MULTIANALYTE TEST ELEMENTS AND METHOD FOR USE THEREOF | |
| BRPI0814343A2 (pt) | Materiais e métodos para a seleção da sexagem do esperma | |
| UA105760C2 (uk) | Антитіло проти bst2 | |
| UY37757A (es) | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante | |
| BR112013023211A2 (pt) | ensaio diagnóstico de anticorpos | |
| Jeffery et al. | Using the laboratory to predict thrombosis in dogs: an achievable goal? | |
| NZ601643A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| ATE437182T1 (de) | Diagnose von allergischen erkrankungen, atopischen erkrankungen und/oder autoimmunerkrankungen durch nachweis von autoantikörpern gegen cd28 in humanem serum | |
| BR112013025287A2 (pt) | ensaios com receptores de esteroide para detectar células tumorais | |
| BR112013006631A2 (pt) | métodos e composições para a avaliação de lesão renal utilizando ácido hialurônico | |
| IN2014MN01760A (https=) | ||
| Martín-Martín et al. | Comparison between enzyme-linked immuno-sorbent assay and multiplex assay for serological markers of Celiac Disease detection | |
| Murray et al. | Demonstration of the specificity of human autoantibody responses to tumor-associated antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |